Genuair^®/Pressair^® Inhaler in COPD: The Patient Perspective

References

• Global initiative for chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report [Internet]. 2018 [cited 2018 Apr 1]. Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
   Google Scholar
• Vincken W, Dekhuijzen PR, Barnes P, et al. The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 2010;19:10–20. doi: 10.4104/pcrj.2009.00062.
   PubMedGoogle Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938. doi: 10.1016/j.rmed.2011.01.005.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:1601794. doi: 10.1183/13993003.01794-2016.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Corrigan CJ, Barnes PJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099–1103. doi: 10.1016/j.rmed.2011.03.012.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pistolesi M, Usmani OS. Recent advances in capsule-based dry powder inhaler technology. Multidiscip Respir Med. 2017;12:11.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–1343. doi: 10.1164/rccm.201604-0733OC.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2018 [Internet]. 2018 [cited 2018 Apr 1]. Available from: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf.
   Google Scholar
• Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5:1–149.
   PubMedGoogle Scholar
• Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16:135.
   PubMed Web of Science ®Google Scholar
• Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(1):CD002170.
   PubMedGoogle Scholar
• Chrystyn H, Small M, Milligan G, et al. Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365. doi: 10.1016/j.rmed.2013.09.021.
   PubMed Web of Science ®Google Scholar
• van Boven JF, Chavannes NH, van der Molen T, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108:103–113. doi: 10.1016/j.rmed.2013.08.044.
   PubMed Web of Science ®Google Scholar
• van der Palen J. Genuair® in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler. Ther Deliv. 2014;5:795–806. doi: 10.4155/tde.14.49.
   PubMedGoogle Scholar
• electronic Medicines Compendium (eMC). Eklira Genuair 322 micrograms inhalation powder: summary of product characteristics (SmPC) [Internet]. 2012 [cited 2018 Apr 1]. Available from: https://www.medicines.org.uk/emc/product/4302.
   Google Scholar
• electronic Medicines Compendium (eMC). Duaklir Genuair 340 micrograms/12 micrograms inhalation powder: summary of product characteristics (SmPC) [Internet]. 2014 [cited 2018 Mar 12]. Available from: https://www.medicines.org.uk/emc/product/3562.
   Google Scholar
• U.S. Food & Drug Administration (FDA). TUDORZATM PRESSAIRTM (aclidinium bromide inhalation power): highlights of prescribing information [Internet]. 2012 [cited 2018 Jul 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdf.
   Google Scholar
• Krüger P, Ehrlein B, Zier M, et al. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J. 2014;44(Suppl. 58):(Abstract 4635).
   Google Scholar
• Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832–1837. doi: 10.1016/j.rmed.2009.07.006.
   PubMed Web of Science ®Google Scholar
• Plugge J, Basaldella U, Fyrnys B, et al. Drug product performance after simulated patient handling of an inhalation powder using and LAMA/LABA combination in a dry powder inhaler. Thorax. 2016;71(Suppl. 3):A247 (Abstract P289).
   PubMedGoogle Scholar
• Linne-Geyer S, Stahl K, Pieper T. In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler. Thorax. 2016;71(Suppl. 3):A249–A251 (Abstract P291). doi: 10.1136/thoraxjnl-2016-209333.434.
   Google Scholar
• Block K, Floger S, Fyrnys B, et al. Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device. Eur Respir J. 2010;36(Suppl. 54):2037 (Abstract).
   Google Scholar
• Newman SP, Sutton DJ, Segarra R, et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78:322–328. doi: 10.1159/000219676.
   PubMed Web of Science ®Google Scholar
• Gjaltema D, Hagedoorn P, Grasmeijer F, et al. Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler. Eur Respir J. 2013;42(Suppl. 57):(Abstract P3384).
   Google Scholar
• Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci. 1986;17:811–825. doi: 10.1016/0021-8502(86)90035-2.
   Web of Science ®Google Scholar
• Sethi S, Kerwin E, Watz H, et al. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2019;14:667–682. doi: 10.2147/COPD.S189138.
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012;40:830–836. doi: 10.1183/09031936.00225511.
   PubMed Web of Science ®Google Scholar
• Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir. Res. 2011;12:55.
   PubMed Web of Science ®Google Scholar
• Greguletz R, Arlt M, Anke S, et al. The Genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder. Am. J. Respir. Crit. Care Med. 2009;179:A2461.
   Web of Science ®Google Scholar
• Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int. J. Clin. Pract 2012;66:309–317. doi: 10.1111/j.1742-1241.2011.02832.x.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2016;11:7.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. Dry-powder inhalers in patients with persistent airflow limitation: usability and preference. Multidiscip Respir Med. 2016;11:31.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. The economic impact of educational training assessed by the handling questionnaire with three inhalation devices in asthma and chronic obstructive pulmonary disease patients. Clin. Outcomes Res. 2016;8:171–176.
   PubMed Web of Science ®Google Scholar
• Ohbayashi H, Kudo S, Ishikawa M. Inhaler operability and patient satisfaction regarding Genuair® and Respimat® inhalers for chronic obstructive pulmonary disease: a randomized crossover study. Pulm Ther. 2017;3:173–185. doi: 10.1007/s41030-017-0038-2.
   Google Scholar
• van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10:1023–1031. doi: 10.1517/17425247.2013.808186.
   PubMed Web of Science ®Google Scholar
• Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med. 2015;25:15018.
   PubMed Web of Science ®Google Scholar
• Man KN, Tian Z, Lam DC-L, et al. Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation. Int J Chron Obstruct Pulmon Dis. 2018;13:1949–1963. doi: 10.2147/COPD.S152285.
   PubMed Web of Science ®Google Scholar
• Bournival R, Coutu R, Goettel N, et al. Preferences and inhalation techniques for inhaler devices used by patients with chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv. 2018;31:237–247. doi: 10.1089/jamp.2017.1409.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030–1039. doi: 10.1183/13993003.00216-2016.
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Scheffel G, et al. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care. Int J Chron Obstruct Pulmon Dis. 2018;13:927–936. doi: 10.2147/COPD.S154525.
   PubMed Web of Science ®Google Scholar
• Blasi F, Canonica GW, Centanni S, et al. Genuair® usability test: results of a national public survey of the elderly. COPD. 2016;13:367–371. doi: 10.3109/15412555.2015.1067675.
   PubMedGoogle Scholar
• Blasi F, Canonica GW, Miravitlles M. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? Respir Res. 2017;18:19.
   PubMed Web of Science ®Google Scholar
• Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616–624. doi: 10.1016/j.rmed.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Beier J, Kirsten A-M, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013;10:511–522. doi: 10.3109/15412555.2013.814626.
   PubMedGoogle Scholar
• Hawken N, Torvinen S, Neine M-E, et al. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment. BMC Pulm Med. 2017;17:99.
   PubMed Web of Science ®Google Scholar
• Price D, Keininger DL, Viswanad B, et al. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;13:695–702. doi: 10.2147/COPD.S149404.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium (eMC). Spiriva 18 microgram inhalation powder, hard capsule: summary of product characteristics (SmPC) [Internet]. 2016 [cited 2018 Feb 5]. Available from: https://www.medicines.org.uk/emc/product/1693/smpc.
   Google Scholar
• Electronic Medicines Compendium (eMC). Ultibro Breezhaler: summary of product characteristics (SmPC) [Internet]. 2013 [cited 2018 Mar 12]. Available from: https://www.medicines.org.uk/emc/product/3496/smpc.
   Google Scholar
• U.S. Food & Drug Administration (FDA). ADVAIR DISKUS 100/50, 250/50 and 500/50 (fluticasone propionate and salmeterol) inhalation powder: highlights of prescribing information (PI) [Internet]. 2014 [cited 2018 Apr 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021077s042lbl.pdf.
   Google Scholar
• Electronic Medicines Compendium (eMC). Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed: summary of product characteristics (SmPC) [Internet]. 2014 [cited 2018 Mar 12]. Available from: https://www.medicines.org.uk/emc/product/5423/smpc.
   Google Scholar
• Electronic Medicines Compendium (eMC). Fostair NEXThaler 100/6: summary of product characteristics (SmPC) [Internet]. 2014 [cited 2018 Feb 5]. Available from: https://www.medicines.org.uk/emc/product/3317/smpc.
   Google Scholar
• Electronic Medicines Compendium (eMC). Symbicort Turbohaler 400/12, inhalation powder: package leaflet [Internet]. 2017 [cited 2018 Feb 5]. Available from: https://www.medicines.org.uk/emc/files/pil.6775.pdf.
   Google Scholar